Skip Navigation


JAC Advance Access originally published online on August 18, 2009
Journal of Antimicrobial Chemotherapy 2009 64(4):797-800; doi:10.1093/jac/dkp300
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/4/797    most recent
dkp300v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paul-Satyaseela, M.
Right arrow Articles by Rajagopal, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paul-Satyaseela, M.
Right arrow Articles by Rajagopal, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro antibacterial activities of a novel oxazolidinone, OCID0050

Maneesh Paul-Satyaseela*, Shakti Singh Solanki, Devarajan Sathishkumar, Thirunavukkarasu Bharani, Vijayan Magesh and Sriram Rajagopal

Anti-infectives Discovery, Department of Microbiology, Orchid Research Laboratories Ltd, 476/14, OMR, Sholinganallur, Chennai 600 119 (TN), India

Received 26 May 2009; returned 17 July 2009; revised 21 July 2009; accepted 27 July 2009

* Corresponding author. Tel: (+9144)2450-1474; Fax: (+9144)2450-1650; E-mail: ipm{at}orchidpharma.com or mspaul{at}mikrobe.org

Objectives: In the pursuit of developing a second-generation oxazolidinone, we have identified OCID0050 as a novel oxazolidinone with enhanced activity against bacterial strains resistant to methicillin, vancomycin and linezolid.

Methods: MIC and MBC determinations were performed according to CLSI guidelines. Linezolid-resistant bacterial strains were generated in-house; inoculum effect, pH effect and kill kinetics experiments were performed as per standard protocols.

Results and conclusions: OCID0050 demonstrated better inhibitory potency against many of the tested clinically significant strains by generally showing 2–4-fold lower MICs than linezolid. In addition, it has higher inhibitory activity against linezolid-resistant strains.

Keywords: linezolid resistant , MRSA , VRE


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.